A New Investigational Vaccine
for Chickenpox Prevention
Chickenpox can be a serious illness for young children, but vaccination offers the best protection. The Lullaby-002 Study is evaluating a new investigational vaccine to help prevent chickenpox in healthy children. This global study will compare the safety of the new vaccine with an already approved chickenpox vaccine.
Vaccination is the key to protection from chickenpox for your little ones
Understanding Chickenpox and the Power of Vaccination
Chickenpox is a highly contagious viral infection caused by the varicella-zoster virus, easily spreading through direct contact or airborne transmission when an infected person coughs or sneezes. Symptoms include:
-
Itchy rash and blisters
-
Fever and discomfort
-
Potential serious complications in infants (skin infections, pneumonia, brain inflammation, and in rare cases, death)
The good news? Chickenpox is preventable. Before vaccines, nearly all children contracted chickenpox by adulthood. Today, vaccines with over 90% effectiveness have dramatically reduced cases worldwide. Vaccines work by safely teaching the immune system to recognize and fight the virus without causing disease, while also contributing to herd immunity that protects entire communities.
About the Lullaby Program:
Advancing Chickenpox Prevention
The Lullaby Program is conducting Phase 3 clinical research studies on an investigational chickenpox vaccine. This means:
-
The vaccine has already undergone initial safety testing (Phase 2)
-
This global study will involve healthy children aged 12-15 months to evaluate effectiveness and compare it to Varivax, an approved chickenpox vaccine
-
Diverse participation ensures we understand how the vaccine works across different races, ethnicities, and backgrounds
What requirements are in place to help protect clinical trial participants?
There are rules in place to help protect the rights, safety, and well-being of people who volunteer tor research studies. These rules are put in place to make sure studies follow strict scientific and ethical guidelines.
Before a clinical research study can begin a review board must review the study. This group is called an IRB
or institutional review board. An IRB is made up of doctors, scientists and members of the community
Is Your Child Eligible?
We are looking for healthy children aged 12–15 months who:
.png)
Have never had chickenpox or a chickenpox vaccine
.png)
Have not been vaccinated against measles, mumps, rubella, or hepatitis A
.png)
Are not currently participating in another clinical study
A study doctor will confirm if your child qualifies. We encourage families of all backgrounds to participate, as vaccines may affect children differently based on race, ethnicity, gender, and age
What Participation Involves
Study Overview
Duration
6 months (3-4 clinic visits + 1-2 phone follow-ups)
1
Vaccines Administered:
Your child will receive either the study vaccine or
Varivax, plus up to 3 other routine childhood vaccines based on your country's immunization schedule
2
Safety Monitoring:
-
30-minute observation after vaccination
-
Regular health check-ups throughout the study
-
Electronic diary for tracking side effects at home
3
*
Potential Side Effects
Like all vaccines, possible reactions may include:
-
Temporary pain, redness, or swelling at injection site
-
These typically resolve within days
Why participate in this study
By joining this study, you’ll help advance research on safe and accessible vaccines for children worldwide. Your child’s participation could contribute to future medical breakthroughs.
.png)
Advance research for safer, more accessible chickenpox vaccines
.png)
Contribute to global health knowledge
.png)
Protect future generations through scientific progress
Your child's participation could make a lasting difference
Is this mandatory?
Study participation is voluntary. By contacting us, your child is under no obligation to take part in the study.
Looking for more Information?
To learn more about the Lullaby Program, please watch this video:
Contact us:
Michigan Center of Medical Research
(248) 747-4383
Site Location:
Medical Center Pediatrics
30400 Telegraph Rd #101,
Bingham Farms, MI 48025
Principal Investigator:
Dr. Martin Levinson